Arthritis and Inflammation
We are trying to better understand the process of pain, inflammation and joint damage in the development of rheumatoid arthritis. Our studies have led to development of antibodies that an intervene in the inflammatory process and these are being commercialised by Garvan spin-off G2 Therapies Ltd. Other projects are based on dissecting the immune cells’ signalling pathways, again with the express purpose of finding points of intervention that may help control inflammatory conditions, such as asthma, arthritis and multiple sclerosis.
Staff
|
|
Research Assistant |
|
|
|
|
|
News
Garvan student receives recognition at international conference
11 Jul 2006
Bennett Shum, PhD student in Garvan's Immunology & Inflammation Research Program, has been awarded the ICF Outstanding Scholar Award. Bennett & colleagues recently found a link between Asthma and Obesity, a fatty acid binding protein called aP2.
Garvan Scientists discover exclusivity of enzyme found in immune cells
31 Mar 2006
Kate Jeffrey and colleagues in Garvan's Immunology and Inflammation Program have discovered a finding which has major implications for the design of a new class of anti-inflammatory drugs.
Sydney scientists discover & license breakthrough anti-inflammatory treatment
08 Feb 2006
Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma.
